Search results for " risk"

showing 10 items of 3823 documents

Risk factors for refractory Kawasaki disease: clinical records of the paediatric clinic of palermo

2014

Kawasaki disease (KD) is an acute, self-limited febrile illness that mainly affecting small- to medium-sized vessels and occurs in early childhood. The etiology is currently unknown, however it likely results from an immunologic response triggered by microbial agents, with documented genetic susceptibility. Intravenous administration of immunoglobulin (IVIG) is the gold standard therapy for coronary arteritis in the acute phase of KD; some patients do not respond to IVIG and coronary aneurysms continue to develop in 5%. The most serious complications are coronary vasculitis and aneurysms. 15% of these patients do not respond to IVIG (Refractory KD:RMK) and have a higher risk of aneurysms.

medicine.medical_specialtyPediatricsbiologybusiness.industryGold standardmedicine.diseaseRheumatologySettore MED/38 - Pediatria Generale E SpecialisticaRefractoryRheumatologyhemic and lymphatic diseasesInternal medicinePoster PresentationPediatrics Perinatology and Child HealthmedicineGenetic predispositionEtiologybiology.proteinImmunology and AllergyKawasaki diseaseKawasaki disease risk factorsPediatrics Perinatology and Child HealthAntibodyVasculitisbusinessPediatric Rheumatology
researchProduct

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

2016

Abstract Background: Management of anemia is a common therapeutic challenge in patients with myelodysplastic syndromes (MDS). Luspatercept (ACE-536), a fusion protein containing modified activin receptor type IIB, is being developed for treatment of anemia in lower-risk MDS. Luspatercept binds GDF11 and other TGF-β superfamily ligands to promote late-stage erythroid differentiation and increase hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014 and Attie K, Am J Hematol, 2014). Aims: This is an ongoing, phase 2, multicenter, open-label study to evaluate the effects of luspatercept in patient (pts) with low-intermediate risk MDS. Endpoints included erythroid response (IWG HI-E), RBC transfus…

medicine.medical_specialtyPediatricsbusiness.industryAnemiaMyelodysplastic syndromesImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyhemic and lymphatic diseasesPharmacodynamicsInternal medicineLuspaterceptCohortmedicineIntermediate riskbusinessLenalidomidemedicine.drugBlood
researchProduct

Late-asthma onset and associated factors

2016

Although asthma is usually considered to originate in childhood, adult-onset is being increasingly reported. Aim: to assess factors associated to early- (<18 yrs) and late-onset (≥18 yrs) asthma. Methods: Data from a web-based Italian severe/uncontrolled asthma (SUA) registry (released in 2014), including 577 SUA subjects from 6 clinical and epidemiological Italian centres (Pisa1, Perugia, Ancona, Verona, Palermo, Pisa2). Results: 77.5% of SUA subjects had a late-onset asthma. Among subjects with early-onset asthma there were higher frequencies of allergic asthma (92.1 vs 76.4%), asthma familiarity (52.8 vs 42.8%), seasonal symptoms (51.3 vs 27.6%), active smoking habits (8.5 vs 4.4%) and u…

medicine.medical_specialtyPediatricsbusiness.industryOccupational riskOverweightmedicine.diseaseLower riskObesityrespiratory tract diseasesAtopyEpidemiologymedicinemedicine.symptombusinessOccupational asthmaAsthma6.1 Epidemiology
researchProduct

Update in the Percutaneous Management of Coronary Chronic Total Occlusions

2018

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been rapidly evolving during recent years. With improvement in equipment and techniques, high success rates can be achieved at experienced centers, although overall success rates remain low. Prospective, randomized-controlled data regarding optimal use and indications for CTO PCI remain limited. CTO PCI should be performed when the anticipated benefit exceeds the potential risk. New high-quality studies of the clinical outcomes and techniques of CTO PCI are needed, as is the expansion of expert centers and operators that can achieve excellent clinical outcomes in this challenging patient and lesion subgroup. In…

medicine.medical_specialtyPercutaneousbusiness.industryPotential riskmedicine.medical_treatmentTreatment outcomePercutaneous coronary intervention030204 cardiovascular system & hematologyCABG = coronary artery bypass grafting CTA = computed tomography angiography CTO = chronic total occlusion IVUS = intravascular ultrasound MACE = major adverse cardiac event(s) MT = medical therapy OMT = optimal medical therapy PCI = percutaneous coronary intervention03 medical and health sciencessurgical procedures operative0302 clinical medicineChronic diseaseCoronary occlusionConventional PCImedicinecardiovascular diseases030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessProspective cohort studyIntensive care medicine
researchProduct

SUBFRACTIONS AND SUBPOPULATIONS OF HDL: AN UPDATE

2014

High-density lipoproteins (HDL) are classified as atheroprotective because they are involved in transport of cholesterol to the liver, known as "reverse cholesterol transport (RCT)" exerting antioxidant and anti-inflammatory activities. There is also evidence for cytoprotective, vasodilatory, antithrombotic, and anti-infectious activities for these lipoproteins. HDLs are known by structural, metabolic and biologic heterogeneity. Thus, different methods are able to distinguish several subclasses of HDL. Different separation techniques appear to support different HDL fractions as being atheroprotective or related with lower cardiovascular (CV) risk. However, HDL particles are not always prote…

medicine.medical_specialtyPharmacologyBiologySystemic inflammationBiochemistrychemistry.chemical_compoundRisk FactorsInternal medicineDrug DiscoveryAntithromboticmedicineAnimalsHumansHdl functionalityPharmacologyCholesterolOrganic ChemistryReverse cholesterol transportBiomarker (cell)EndocrinologychemistryCardiovascular DiseasesMolecular MedicineSeparation methodlipids (amino acids peptides and proteins)Hdl subfractionscardiovascular risk electrophoresis high-density lipoprotein nuclear magnetic resonance proteome subclasses subfractions ultracentrifugation.medicine.symptomLipoproteins HDL
researchProduct

Associations Between Accelerometer-Based Free-Living Walking and Self-Reported Walking Capability Among Community-Dwelling Older People

2021

The authors examined whether accelerometer-based free-living walking differs between those reporting walking modifications or perceiving walking difficulty versus those with no difficulty. Community-dwelling 75-, 80-, or 85-year-old people (N = 479) wore accelerometers continuously for 3–7 days, and reported whether they perceived no difficulties, used walking modifications, or perceived difficulties walking 2 km. Daily walking minutes, walking bouts, walking bout intensity and duration, and activity fragmentation were calculated from accelerometer recordings, and cut points for increased risk for perceiving walking difficulties were calculated using receiver operating characteristic analys…

medicine.medical_specialtyPhysical Therapy Sports Therapy and RehabilitationWalkingAccelerometercompensation03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationAccelerometryliikuntakykymedicineHumans030212 general & internal medicineMobility Limitationwalking accumulationAgedAged 80 and overReceiver operating characteristic analysisRehabilitation030229 sport sciencesmobilitykävelyIncreased riskDifficulty walkingIndependent LivingSelf ReportGeriatrics and GerontologyOlder peoplePsychologyhuman activitiesGerontologyfyysinen aktiivisuusikääntyneetJournal of Aging and Physical Activity
researchProduct

Corrigendum to ‘Sleep and sleepiness in shift-working tram drivers’[Applied Ergonomics Sleep and sleepiness in shift-working tram drivers 88 (2020) 1…

2021

medicine.medical_specialtyPhysical medicine and rehabilitationmedicineHuman factors and ergonomicsPhysical Therapy Sports Therapy and RehabilitationHuman Factors and ErgonomicsSafety Risk Reliability and QualityPsychologyEngineering (miscellaneous)Sleep in non-human animalsApplied Ergonomics
researchProduct

Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric di…

2012

BACKGROUND: Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. OBJECTIVE: To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-alpha in HCV-infected patients without a history of psychiatric disorders. DESIGN: Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) SETTING: 10 university and 11 academic…

medicine.medical_specialtyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineEscitalopram030212 general & internal medicinePsychiatryDepression (differential diagnoses)business.industryIncidence (epidemiology)Absolute risk reductionGeneral MedicineHepatitis Cmedicine.disease3. Good healthTolerability030211 gastroenterology & hepatologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

0128: CHA2DS2-VASc score estimates in-hospital mortality beyond GRACE score after acute myocardial infarction

2016

International audience; Background and aimsCHA2DS2VASc score have recently been suggested to predict death in patients with Atrial Fibrillation (AF). In acute myocardial infarction (AMI), silent AF is more common than symptomatic AF and associated with poor prognosis. In patients with AMI, we aimed to assess the distribution of CHA2DS2VASc score in patients with silent or symptomatic AF and the association of the score with mortality.Methods849 consecutive AMI were prospectively analyzed by continuous ECG monitoring (CEM) 30 sec. Symptomatic AF was defined as any AF occurring on ECG during the hospital stay, resulting in clinical symptoms or need for urgent cardioversion. The population was…

medicine.medical_specialtyPoor prognosismedicine.medical_treatment030204 cardiovascular system & hematologyCardioversion03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineAtrial FibrillationmedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionFramingham Risk ScoreIn hospital mortalitybusiness.industryAtrial fibrillation[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthmyocardial infarctionCHA2DS2–VASc scoreCardiologyCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Evaluation of C-Reactive Protein in Primary and Secondary Prevention

2007

Inflammation is pivotal in atherosclerosis, and C-reactive protein (CRP) is an inflammatory marker that predicts cardiovascular events. Several population-based studies have demonstrated that baseline CRP levels predict future cardiovascular events. CRP testing may thus have a major adjunctive role in the global assessment of cardiovascular risk. Recently, the National Cholesterol Education Program, through the Adult Treatment Panel III guidelines, identified CRP and another marker of inflammation, the fibrinogen, as “emerging risk factors,” suggesting that their measurement may improve the estimations of absolute risk obtained using the traditional cardiovascular risk factors. In terms of…

medicine.medical_specialtyPopulationDiseaseFibrinogenGeneral Biochemistry Genetics and Molecular BiologyRisk FactorsInternal medicineHumansMass ScreeningMedicineeducationNational Cholesterol Education Programeducation.field_of_studyFramingham Risk Scorebiologybusiness.industryC-reactive proteinAbsolute risk reductionGeneral MedicineAtherosclerosismedicine.diseaseC-Reactive ProteinPhysical therapybiology.proteinMetabolic syndromebusinessmedicine.drugJournal of Investigative Medicine
researchProduct